Immunotherapy Clinical Trials

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site


CC-16047   NCT02834052 A phase I/II trial of pembrolizumab (MK-3475) and poly-ICLC in patients with metastatic mismatch repair-proficient (MRP) colon cancer A. Nayak Ashlyn Stevenson Phase 1: All solid tumors, following at least one therapy  Phase 2: Mismatch Repair Proficient “MRP” (includes microsatellite stable [MSS] and MSI-low) colon cancer that has progressed following at least two lines of therapy I/II